Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 7/2019

01-07-2019 | Human Immunodeficiency Virus | Original Paper

Predicting Pharmacist Dispensing Practices and Comfort Related to Pre-exposure Prophylaxis for HIV Prevention (PrEP)

Authors: B. E. Meyerson, P. C. Dinh Jr, J. D. Agley, B. J. Hill, D. N. Motley, G. A. Carter, W. Jayawardene, P. T. Ryder

Published in: AIDS and Behavior | Issue 7/2019

Login to get access

Abstract

To identify factors associated with pharmacist dispensing practice and comfort counseling patients about pre-exposure prophylaxis for HIV prevention (PrEP). Cross-sectional 2016 census of Indiana managing pharmacists measured PrEP awareness, comfort dispensing and counseling patients. Modified Poisson models with robust error variance estimated relative risks and confidence intervals. 15.8% of 284 pharmacists had dispensed PrEP and 11.6% had consulted about it. Dispensing and comfort counseling were associated with confidence in knowledge about PrEP medication adherence and adverse effects of PrEP medication; awareness about PrEP before the survey, number of full time pharmacists in their pharmacy, and increases in new HIV cases from 2015 to 2016 in communities served. Comfort counseling about PrEP was associated with the belief that pharmacists can be an important resource for HIV and HCV treatment.
Literature
1.
Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.CrossRefPubMedPubMedCentral
2.
3.
4.
Young I, Li J, McDaid L. Awareness and willingness to use HIV pre-exposure prophylaxis amongst gay and bisexual men in Scotland: implications for biomedical HIV prevention. PLoS ONE. 2013;8(5):e64038.CrossRefPubMedPubMedCentral
5.
Jayakumaran JS, Aaron E, Gracely EJ, Schriver E, Szep Z. Knowledge, attitudes, and acceptability of pre-exposure prophylaxis among individuals living with HIV in an urban HIV clinic. PLoS ONE. 2016;11(2):e0145670.CrossRefPubMedPubMedCentral
6.
Strauss BB, Greene GJ, Phillips G, Bhatia R, Madkins K, Parsons JT, Mustanski B. Exploring patterns of awareness and use of HIV pre-exposure prophylaxis among young men who have sex with men. AIDS Behav. 2017;21(5):1288–98.CrossRefPubMedPubMedCentral
7.
Ross I, Mejia C, Melendez J, Chan PA, Nunn AC, Powderly W, Goodenberger K, Liu J, Mayer KH, Patel RR. Awareness and attitudes of pre-exposure prophylaxis for HIV prevention among physicians in Guatemala: implications for country-wide implementation. PLoS ONE. 2017;12(3):e0173057.CrossRefPubMedPubMedCentral
8.
Smith DK, Mendoza MCB, Stryker JE, Rose CE. PrEP awareness and attitudes in a national survey of primary care clinicians in the United States, 2009-2015. PLoS ONE. 2016;11(6):e0156592.CrossRefPubMedPubMedCentral
9.
Calabrese SK, Earnshaw VA, Underhill K, Hansen NB, Dovidio JF. The impact of patient race on clinical decisions related to prescribing HIV pre-exposure prophylaxis (PrEP): assumptions about sexual risk compensation and implications for access. AIDS Behav. 2014;18(2):226–40.CrossRefPubMedPubMedCentral
10.
11.
12.
Moffat C, Matyanga J. The role of the pharmacist in pre-exposure prophylaxis. Pharmacol Pharm. 2014;5:225–8.CrossRef
13.
Shaeer KM, Sherman EM, Shafiq S, Hardigan P. Exploratory survey of Florida pharmacists’ experience, knowledge and perceptions of HIV pre-exposure prophylaxis. Am J Pharm Assoc. 2014;54(6):610–7.CrossRef
14.
Hammett TM, Phan S, Gaggin J, Case P, Zaller N, Lutnick A, Kral AH, Fedorova EV, Heimer R, Small W, Pollini R, Beletsky L, Latkin C, de Jarlais DC. Pharmacies as providers of expanded health services for people who inject drugs: a review of laws, policies and barriers in six countries. BMC Health Serv Res. 2014;14(261):1–11.
15.
Hogue MD, Grabenstein JD, Foster SL, Rothholz MC. Pharmacist involvement with immunizations: a decade of professional advancement. J Am Pharm Assoc. 2003;2006(46):168–79.
16.
Murphy P, Cocohoba J, Tang A, Pietrandoni G, Hou J, Guglielmo BJ. Impact of HIV-specialized pharmacies on adherence and persistence with antiretroviral therapy. AIDS Patient Care STDS. 2012;26:526–31.CrossRefPubMedPubMedCentral
17.
Meyerson BE, Ryder PT, Richey-Smith C. Achieving pharmacy-based public health: a call for public health engagement. Public Health Rep. 2013;128:140–3.CrossRefPubMedPubMedCentral
18.
Bunting BA, Smith BH, Sutherland SE. The Ashville Project: clinical and economic outcomes of a community-based long-term medication therapy management program for hypertension and dyslipidemia. J Am Pharm Assoc. 2003;2008(48):23–31.
19.
Snella KA, Canales AE, Irons BK, Sleeper-Irons RB, Villarreal MC, Levi-Derrick VE, et al. Pharmacy- and community-based screenings for diabetes and cardiovascular conditions in high-risk individuals. J Am Pharm Assoc. 2003;2006(46):370–7.
20.
21.
Meyerson BE, Davis A, Agley JD, Shannon DJ, Lawrence CA, Ryder PT, Ritchie K, Gassman R. Predicting pharmacy syringe sales to people who inject drugs: policy practice and perceptions 2018. Int J Drug Policy. 2018;56:46–53.CrossRefPubMedPubMedCentral
22.
Meyerson BE, Ryder PT, Von Hippel C, Coy K. We can do more than just sell the test: pharmacist perspectives about over the counter rapid HIV tests. AIDS Behav. 2013;17(6):2109–13.CrossRefPubMed
23.
Ryder PT, Meyerson BE, Coy KC, von Hippel CD. Pharmacists’ perspectives on HIV testing in community pharmacies. J Am Pharm Assoc. 2013;53:595–600.CrossRef
24.
Amesty S, Blaney S, Crawford ND, Rivera AV, Fuller C. Pharmacy staff characteristics associated with support for pharmacy based HIV testing. AIDS Patient Care STDs. 2012;26(9):526–31.CrossRef
25.
Petroll AE, Walsh JL, Owczarzak JL, McAuliffe TL, Bogart LM, Kelly JA. PrEP awareness, familiarity, comfort, and prescribing experience among US primary care providers and HIV specialists. AIDS Behav. 2017;21(5):1256–67.CrossRefPubMedPubMedCentral
26.
Spector AY, Remien RH, Tross S. PrEP in substance abuse treatment: a qualitative study of treatment provider perspectives. Subst Abuse Treat Prevent Policy. 2015;10(1):1–10.CrossRef
27.
Carter GA, Jayawardene W, Agley J, Garcia J, Miller W, Sherwood-Laughlin, C, Meyerson BE. Development of a 10-item tool to identify APN readiness to prescribe pre-exposure prophylaxis. (in review).
28.
Matyanga CMJ, Khoza S, Gavi S. HIV pre-exposure prophylaxis: pharmacists knowledge, perception and willingness to adopt future implementation in a Zimbabwean urban setting. East Cent Afr J Pharm Sci. 2014;17(1):3–9.
29.
Atkinson J, Sánchez Pozo A, Rekkas D, Volmer D, Hirvonen J, Bozic B, Skowron A, Mircioiu C, Sandulovici R, et al. Hospital and community pharmacists’ perceptions of which competencies are important for their practice. Pharm (Basel). 2016;4(2):21.PubMedCentral
30.
Nash RE, Chalmers L, Stupans I, Brown N. Knowledge, use and perceived relevance of a profession’s Competency Standards; implications for Pharmacy Education. Int J Pharm Pract. 2016;24(6):390–402.CrossRefPubMed
31.
Unni EJ, Lian N, Kuykendall W. Understanding community pharmacist perceptions and knowledge about HIV preexposure prophylaxis (PrEP) therapy in a mountain west state. J Am Pharm Assoc. 2016;56:527–32.CrossRef
32.
Yoong D, Naccarato M, Sharma M, Wilton J, Senn H, Tan DHS. Preparing for pre-exposure prophylaxis: perceptions and readiness of Canadian pharmacists for the implementation of HIV pre-exposure prophylaxis. Int J STD AIDS. 2016;27(8):608–16.CrossRefPubMed
33.
Hall HI, Holtgrave DR, Maulsby C. HIV transmission rates from persons living with HIV who are aware and unaware of their infection. AIDS. 2012;26(7):893–6.CrossRefPubMed
34.
Balaji AB, Bowles KE, Le BC, Paz-Bailey G. Oster AM for the NHBS Study Group. High HIV incidence and prevalence and associated factors among young MSM, 2008. AIDS. 2013;27(2):269–78.CrossRefPubMedPubMedCentral
35.
Meyerson BE, Agley JD, Davis A, Jayawardene W, Hoss A, Shannon DJ, Ryder PT, Ritchie K, Gassman R. Predicting pharmacy naloxone stocking and dispensing following a statewide standing order, Indiana. Drug Alcohol Depend. 2016;188:187–92.CrossRef
36.
Agley JD, Meyerson BE, Shannon DJ, Ryder PT, Ritchie K, Gassman R. Using the hybrid method to survey U.S. pharmacists: applying lessons learned to leverage technology. Res Soc Adm Pharm. 2016;13:250–2.CrossRef
37.
38.
39.
Patrick R, Forrest D, Cardenas G, Opoku J, Magnus M, Phillips G, Greenberg A, Metsch L, Kharfen M, et al. Awareness, willingness, and use of pre-exposure prophylaxis among men who have sex with men in Washington, DC and Miami Dade County, FL: National behavioral surveillance, 2011 and 2014. J Acquir Immune Defic Syndr. 2017;75(Supp 3):S375–82.CrossRefPubMedPubMedCentral
40.
Siegler AJ, Mouhanna F, Giler RM, Weiss K, Pembleton E, Guest J, Jones J, Castel A, Yeung H, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017, United States. Ann Epidemiol. 2018;28(12):841–9.CrossRefPubMed
41.
Zou G. A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702–6.CrossRef
42.
Tabachnick BG, Fidell LS. Using multivariate statistics. 6th ed. Boston: Pearson Education; 2013.
43.
Keeter S, Kennedy C, Dimock M, Best J, Craighill P. Gauging the Impact of Growing Nonresponse on Estimates from a National RDD Telephone Survey. Public Opin Q. 2006;70:759–79.CrossRef
44.
Stuart GS, Grimes DA. Social desirability bias in family planning studies: a neglected problem. Contraception. 2009;80(2):108–12.CrossRefPubMed
45.
Blumenthal J, Jain S, Krakower D, Sun X, Young J, Mayer K, Haubrich R. Knowledge is power! Increased provider knowledge scores regarding pre-exposure prophylaxis (PrEP) are associated with higher rates of PrEP prescription and future intent to prescribe PrEP. AIDS Behav. 2015;19(5):802–10.CrossRefPubMedPubMedCentral
46.
Brooks RA, Kaplan RL, Lieber E, Landovitz RJ, Lee SJ, Leibowitz AA. Motivators, concerns and barriers to adoption of pre-exposure prophylaxis for HIV prevention among gay and bisexual men in HIV sero-discordant male relationships. AIDS Care. 2011;23(9):1136–45.CrossRefPubMedPubMedCentral
47.
Bauermeister JA, Meanley S, Pingel E, Soler JH, Harper GW. PrEP awareness and perceived barriers among single young men who have sex with men in the United States. Curr HIV Res. 2013;11(7):520–7.CrossRefPubMedPubMedCentral
48.
49.
Anderson C, Blenkinsopp A, Armstrong M. Feedback from community pharmacy users on the contribution of community pharmacy to improving the public’s health: a systemic review of the peer reviewed a non-peer reviewed literature 1990-2002. Health Expect. 2004;7(3):191–202.CrossRefPubMedPubMedCentral
50.
Snella KA, Canales AE, Irons BK, Sleeper-Irons RB, Villarreal MC, Levi-Derrick VE, et al. Pharmacy- and community-based screenings for diabetes and cardiovascular conditions in high-risk individuals. J Am Pharm Assoc. 2006;46:370–7.CrossRef
51.
Potter MB, Gildengorin G, Wang Y, Wu M, Kroon L. Comparative effectiveness of two pharmacy-based colorectal cancer screening interventions during an annual influenza vaccination campaign. J Am Pharm Assoc. 2010;50:181–7.CrossRef
52.
Letassy N, Dennis V, Lyons TJ, Harrison D, Burton M, Kirkpatrick A. Know your diabetes risk project: student pharmacists educating adults about diabetes risk in a community pharmacy setting. J Am Pharm Assoc. 2010;50:188–94.CrossRef
53.
Patwardhan PD, Chewning BA. Effectiveness of intervention to implement tobacco cessation counseling in community chain pharmacies. J Am Pharm Assoc. 2012;52:507–14.CrossRef
54.
Brown TJ, Todd A, O’Malley C, et al. Community pharmacy-delivered interventions for public health priorities: a systematic review of interventions for alcohol reduction, smoking cessation and weight management, including meta-analysis for smoking cessation. BMJ Open. 2016;6:e009828.CrossRefPubMedPubMedCentral
55.
Hayes Directories, Inc. Hayes Database of Retail Pharmacies. Mission Viejo, California. List published and purchased by authors December 2015.
56.
Metadata
Title
Predicting Pharmacist Dispensing Practices and Comfort Related to Pre-exposure Prophylaxis for HIV Prevention (PrEP)
Authors
B. E. Meyerson
P. C. Dinh Jr
J. D. Agley
B. J. Hill
D. N. Motley
G. A. Carter
W. Jayawardene
P. T. Ryder
Publication date
01-07-2019
Publisher
Springer US
Published in
AIDS and Behavior / Issue 7/2019
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-018-02383-7

Other articles of this Issue 7/2019

AIDS and Behavior 7/2019 Go to the issue

Original Paper

The Association Between Disclosure of Same Sex Behavior to Healthcare Providers and PrEP Awareness Among BMSM in Baltimore

Original Paper

Stigma, the Media, and Pre-exposure Prophylaxis for HIV Prevention: Observations for Enhancing Knowledge Translation and Resisting Stigma in the Canadian Context

Original Paper

High Adherence to HIV Pre-exposure Prophylaxis and No HIV Seroconversions Despite High Levels of Risk Behaviour and STIs: The Australian Demonstration Study PrELUDE

Original Paper

Lessons from PrEP: A Qualitative Study Investigating How Clinical and Policy Experts Weigh Ethics and Evidence When Evaluating Preventive Medications for Use in Pregnant and Breastfeeding Women

Original Paper

PrEP in the Real World: Predictors of 6-Month Retention in a Diverse Urban Cohort

Original Paper

Differences in Medical Mistrust Between Black and White Women: Implications for Patient–Provider Communication About PrEP
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits